IL6 and COVID-19: While our exploratory, unadjusted analyses did not demonstrate a mortality benefit for dexamethasone or other agents, this contrasts with large randomized trials reporting benefit for corticosteroids, IL-6, and JAK inhibitors in severe COVID-19 (Ref).